Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.9 -3.05 (-1.13%) Market Cap: 34.30 Bil Enterprise Value: 33.17 Bil PE Ratio: 0 PB Ratio: 1,063.60 GF Score: 78/100

Alnylam Pharmaceuticals Inc "RNAi Roundtable" Webcast Series: Patisiran & Vutrisiran, for the Treatment of Transthyretin-Mediated Amyloidosis Transcript

Sep 16, 2019 / 05:00PM GMT
Release Date Price: $84.77 (+1.29%)
Operator

Good day, and welcome to the RNAi Roundtable. Today's conference is being recorded. At this time, I would like to turn the conference over to Josh Brodsky, Director of Investor Relations and Corporate Communications. Please go ahead.

Joshua Brodsky
Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications

Good afternoon, everyone. Thank you for joining us for today's RNAi Roundtable where we'll be discussing patisiran and vutrisiran, RNAi therapeutics in development for the treatment of ATTR amyloidosis.

I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam. With me today are Eric Green, Senior Vice President and General Manager of the TTR Program; Mike, a patient living with hereditary ATTR amyloidosis; John Vest, Executive Director of Clinical Research; and Rena Denoncourt, Senior Director and Program Leader for Vutrisiran.

Today's RNAi Roundtable is the first in a series of roundtables that we'll be hosting over the next few months to review progress across our various programs. Today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot